Oncologist Dr. Mary Horowitz MD-Clinical Researcher Of The Day
In this blog, we are highlighting an up and coming physician-researcher, Dr. Mary Horowitz MD. Dr. Horowitz is a Professor of medicine in the Department of Hematology and Oncology who practices oncology and internal medicine in Medical College of Wisconsin (MCW) in Milwaukee. She received her education from the Medical College Of Wisconsin in Milwaukee, WI, United States. Dr. Mary is a hematology oncologist who specializes in the treatment of Oncology and Internal Medicine.
Listed below are some of the highlights of Dr. Horowitz’s Academic and Professional Qualifications
- Froedtert Memorial Lutheran Hospital
9200 W Wisconsin Ave
Milwaukee, WI 53226
Achievements of Dr. Mary Horowitz
- In June 2006, Dr. Horowitz received MCW’s Distinguished Service Award.
- In 2010, Dr. Horowitz received the American Society of Hematology Mentor Award for guiding, supporting and promoting the training and career development of their junior colleagues.
- She is a member of the editorial boards of the journals Blood, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation
- Dr. Mary has served on the National Cancer Institute’s Cancer Clinical Investigation Review Committee.
- She is the Principal Investigator of the Data and Coordinating Center of the U.S. Blood and Marrow Transplant Clinical Trials Network.
- Dr. Horowitz has given more than 180 invited presentations on the subject of hematopoietic stem cell transplantation.
Dr. Mary is currently conducting 7 clinical trials for investigating better treatments for Multiple Myeloma and CMl. Brief details of the trials are listed below.
- Comparing Peripheral Blood Stem Cell Transplantation Versus Bone Marrow Transplantation in Individuals With Hematologic Cancers – The study is designed as a Phase III, randomized, open label, multicenter, prospective, comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) versus marrow from unrelated donors for transplantation in patients with hematologic malignancies.
- Single Versus Double Umbilical Cord Blood Transplantation in Children With High Risk Leukemia and Myelodysplasia – This study is a Phase III, randomized, open-label, multi-center, prospective study of single umbilical cord blood (UCB) transplantation versus double UCB transplantation in pediatric patients with hematologic malignancies.
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802) – The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating the addition of MMF vs. placebo to systemic corticosteroids as initial therapy for acute GVHD.
- Effectiveness of Etanercept for Idiopathic Pneumonia Syndrome Following Stem Cell Transplantation – The study is designed as a Phase III, multi-center randomized, double-blind, placebo-controlled trial investigating the use of etanercept for the treatment of acute, non-infectious pulmonary dysfunction (IPS) occurring after allogeneic hematopoietic cell transplantation (HCT).
- Fludarabine-based Conditioning for Severe Aplastic Anemia – The purpose of this study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia (SAA) transplanted with marrow from human leukocyte antigen (HLA)-compatible unrelated donors.
- Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) – The study is designed as a phase III, randomized, open label, multicenter, prospective, comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as graft-versus-host disease (GVHD) prophylaxis after human leukocyte antigen (HLA)-matched, related, peripheral blood stem cell transplantation in individuals with hematologic cancer.
- Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) – The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy or single autologous transplant plus maintenance therapy as part of upfront treatment of multiple myeloma (MM).
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) – This study is designed as a combined Phase II/III, randomized, open label, multicenter, prospective comparative study of sirolimus plus prednisone, sirolimus/extracorporeal photopheresis plus prednisone versus sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD.